Select publications
Cassidy J et al. XELOX vs FOLFOX4: Efficacy results from XELOX-1/NO16966,a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium 2007;Abstract 270.
Hecht J et al. Panitumumab antitumor activity in patients with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). Proc ASCO 2006;Abstract 3547.
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Peeters M et al. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer. Program and Abstracts of the 97th Annual Meeting of the American Association for Cancer Research 2006;Abstract CP-1.
Saltz LB et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Presentation. Gastrointestinal Cancers Symposium 2007;Abstract 238.
